In a cross-sectional study, the collection of serum samples from 339 MS patients immediately before a scheduled RTX infusion, ADAs were detected in 37% of relapsing/remitting MS and 26% in progressive forms of MS. This evidence concerns the gene AGPS and myeloid sarcoma.